BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21325458)

  • 21. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility.
    Hvidman HW; Bentzen JG; Thuesen LL; Lauritsen MP; Forman JL; Loft A; Pinborg A; Nyboe Andersen A
    Hum Reprod; 2016 May; 31(5):1034-45. PubMed ID: 26965431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer.
    Chai J; Howie AF; Cameron DA; Anderson RA
    Eur J Cancer; 2014 Sep; 50(14):2367-74. PubMed ID: 25027307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization.
    Kunt C; Ozaksit G; Keskin Kurt R; Cakir Gungor AN; Kanat-Pektas M; Kilic S; Dede A
    Arch Gynecol Obstet; 2011 Jun; 283(6):1415-21. PubMed ID: 21562964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.
    Partridge AH; Ruddy KJ; Gelber S; Schapira L; Abusief M; Meyer M; Ginsburg E
    Fertil Steril; 2010 Jul; 94(2):638-44. PubMed ID: 19409543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy.
    Dillon KE; Sammel MD; Prewitt M; Ginsberg JP; Walker D; Mersereau JE; Gosiengfiao Y; Gracia CR
    Fertil Steril; 2013 Feb; 99(2):477-83. PubMed ID: 23084267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of cancer therapies on ovarian reserve.
    Gracia CR; Sammel MD; Freeman E; Prewitt M; Carlson C; Ray A; Vance A; Ginsberg JP
    Fertil Steril; 2012 Jan; 97(1):134-40.e1. PubMed ID: 22137491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
    Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V
    Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure.
    Knauff EA; Eijkemans MJ; Lambalk CB; ten Kate-Booij MJ; Hoek A; Beerendonk CC; Laven JS; Goverde AJ; Broekmans FJ; Themmen AP; de Jong FH; Fauser BC;
    J Clin Endocrinol Metab; 2009 Mar; 94(3):786-92. PubMed ID: 19066296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of breast cancer on anti-mullerian hormone levels in young women.
    Su HI; Flatt SW; Natarajan L; DeMichele A; Steiner AZ
    Breast Cancer Res Treat; 2013 Jan; 137(2):571-7. PubMed ID: 23224236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments.
    Silva C; Ribeiro Rama AC; Reis Soares S; Moura-Ramos M; Almeida-Santos T
    J Ovarian Res; 2019 Oct; 12(1):102. PubMed ID: 31672154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum antimüllerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation.
    Sermondade N; Sonigo C; Sifer C; Valtat S; Ziol M; Eustache F; Grynberg M
    Fertil Steril; 2019 Feb; 111(2):357-362. PubMed ID: 30527837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study.
    Brougham MF; Crofton PM; Johnson EJ; Evans N; Anderson RA; Wallace WH
    J Clin Endocrinol Metab; 2012 Jun; 97(6):2059-67. PubMed ID: 22472563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women.
    Freeman EW; Sammel MD; Lin H; Gracia CR
    J Clin Endocrinol Metab; 2012 May; 97(5):1673-80. PubMed ID: 22378815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antral follicle count (AFC) and serum anti-Müllerian hormone (AMH) are the predictors of natural fecundability have similar trends irrespective of fertility status and menstrual characteristics among fertile and infertile women below the age of 40 years.
    Khan HL; Bhatti S; Suhail S; Gul R; Awais A; Hamayun H; Enver F; Abbas S; Hassan Z; Nisar R; Sardar S; Asif W
    Reprod Biol Endocrinol; 2019 Feb; 17(1):20. PubMed ID: 30744650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan.
    Birch Petersen K; Hvidman HW; Forman JL; Pinborg A; Larsen EC; Macklon KT; Sylvest R; Andersen AN
    Hum Reprod; 2015 Oct; 30(10):2364-75. PubMed ID: 26311148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five-year study assessing the clinical utility of anti-Müllerian hormone measurements in reproductive-age women with cancer.
    Palinska-Rudzka KE; Ghobara T; Parsons N; Milner J; Lockwood G; Hartshorne GM
    Reprod Biomed Online; 2019 Oct; 39(4):712-720. PubMed ID: 31471141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical value of serum anti-mullerian hormone and inhibin B in prediction of ovarian response in patients with polycystic ovary syndrome.
    Zhang F; Liu XL; Rong N; Huang XW
    J Huazhong Univ Sci Technolog Med Sci; 2017 Feb; 37(1):70-73. PubMed ID: 28224431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The physiology and clinical utility of anti-Mullerian hormone in women.
    Dewailly D; Andersen CY; Balen A; Broekmans F; Dilaver N; Fanchin R; Griesinger G; Kelsey TW; La Marca A; Lambalk C; Mason H; Nelson SM; Visser JA; Wallace WH; Anderson RA
    Hum Reprod Update; 2014; 20(3):370-85. PubMed ID: 24430863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian reserve after treatment with alkylating agents during childhood.
    Thomas-Teinturier C; Allodji RS; Svetlova E; Frey MA; Oberlin O; Millischer AE; Epelboin S; Decanter C; Pacquement H; Tabone MD; Sudour-Bonnange H; Baruchel A; Lahlou N; De Vathaire F
    Hum Reprod; 2015 Jun; 30(6):1437-46. PubMed ID: 25801499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.